Street Calls of the Week
Investing.com - Jones Trading initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and a $130.00 price target, highlighting the company’s potential in the Wilson’s Disease treatment market. The stock, currently trading at $100.96 and near its 52-week high of $105, has delivered an impressive 1,852% return over the past year. According to InvestingPro, analyst targets range from $85 to $142, with the company maintaining a GOOD financial health score despite current unprofitability.
The clinical-stage company acquired ALXN1840 in October 2024, a drug previously discontinued by AstraZeneca despite a successful Phase 3 trial. Monopar aims to revive the program by potentially correcting the methodology used to calculate copper balance in Wilson’s Disease patients.
Jones Trading estimates the Wilson’s Disease market in the US and EU5 could be worth more than $2.5 billion. The firm projects adjusted peak sales of approximately $500 million, based on a 70% probability of success and 25% market penetration, despite competition from at least four other copper chelators.
The analysis indicates Monopar could file for regulatory approval in the first half of 2026, though the firm acknowledges regulatory risks remain as the calculation for copper mobilization requires FDA approval.
Jones Trading views Monopar’s acquisition of ALXN1840 as a potential turnaround story, describing it as "one man’s discontinued program is another man’s potentially first approved drug."
In other recent news, Monopar Therapeutics announced a stock offering expected to generate approximately $100 million in gross proceeds. The offering includes over a million shares of common stock and pre-funded warrants. This financial move comes alongside a series of analyst upgrades for Monopar. Raymond James raised its price target for the company to $142 from $80, maintaining a Strong Buy rating. H.C. Wainwright also increased its target to $105 from $70, while Piper Sandler adjusted its target to $95 from $76, both maintaining positive ratings. BTIG followed suit, raising its target to $104 from $87, with a continued Buy rating. These upgrades were influenced by a newly published analysis in the Journal of Hepatology, which reassessed data from a Phase 2 study involving Wilson disease treatments. The analysis challenged previous conclusions about the treatment’s effectiveness, leading to increased confidence from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.